Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SDCBP | O00560 | 1/20 | 0.38 |
| ▸ | SDC2 | P34741 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734807 | 1.00 | ALDH1A1 (0.46) | ALDH1A1POLBSMN1; SMN2MMELMNA | |
| SCHEMBL29851772 | 0.83 | TP53 (0.46) | ALDH1A1POLBSMN1; SMN2MMELMNA | |
| SCHEMBL16481929 | 0.83 | SMN1; SMN2 (0.44) | ALDH1A1POLBSMN1; SMN2MMELMNA | |
| SCHEMBL6376785 | 0.83 | TP53 (0.46) | ALDH1A1POLBSMN1; SMN2MMELMNA | |
| SCHEMBL28452533 | 0.83 | MME (0.46) | ALDH1A1POLBSMN1; SMN2MMECA2 | |
| SCHEMBL28452532 | 0.83 | MME (0.46) | ALDH1A1POLBSMN1; SMN2MMECA2 | |
| SCHEMBL23432970 | 0.82 | MME (0.43) | ALDH1A1POLBMME | |
| SCHEMBL13957532 | 0.82 | ALDH1A1 (0.35) | ALDH1A1POLBSMN1; SMN2MMELMNA | |
| SCHEMBL19486077 | 0.82 | CCR1 (0.36) | ALDH1A1POLBSMN1; SMN2MMEGAA | |
| SCHEMBL13957529 | 0.81 | ALDH1A1 (0.39) | ALDH1A1POLBSMN1; SMN2MMEGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112135812-B | Ketamine derivatives and pharmaceutical compositions thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-01-18 | — | — | CN | claimed |
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2004-05-20 | — | — | US | claimed |
| EP-1294747-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2003-03-26 | — | — | EP | claimed |
| WO-2002002596-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2002-01-10 | — | — | WO | claimed |
| EP-4681777-A2 | PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2026-01-21 | — | — | EP | disclosed |
| EP-3737665-B1 | PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF | XWPHARMA LTD (KY) | 2026-01-07 | — | — | EP | disclosed |
| US-20250122149-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2025-04-17 | — | — | US | disclosed |
| US-12209060-B2 | Ketamine derivatives and compositions thereof | XWPharma Ltd. (KY) | 2025-01-28 | — | — | US | disclosed |
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| CN-117858867-A | SARS-COV-2 MPRO inhibitor compounds | 赫普泰雅治疗有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4313305-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2004-05-20 | — | — | US | disclosed |
| EP-1294747-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002596-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2002-01-10 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209060-B2 | Ketamine derivatives and compositions thereof | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885POLB 3849/4885SMN1; SMN2 581/4885 |
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, PML, APLNR | ALDH1A1 2688/4885POLB 279/4885SMN1; SMN2 3509/4885 |
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | ACE2, SARS1, ACE | ALDH1A1 2710/4885POLB 590/4885SMN1; SMN2 3131/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ALDH1A1 4236/4885POLB 578/4885SMN1; SMN2 2633/4885 |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | ALDH1A1 1787/4885POLB 347/4885SMN1; SMN2 3365/4885 |
| US-20250122149-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885POLB 3849/4885SMN1; SMN2 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.